Vietnam
· Delayed Price · Currency is VND Imexpharm Statistics
Total Valuation
Imexpharm has a market cap or net worth of VND 7.92 trillion. The enterprise value is 7.85 trillion.
| Market Cap | 7.92T |
| Enterprise Value | 7.85T |
Important Dates
The next estimated earnings date is Friday, July 18, 2025.
| Earnings Date | Jul 18, 2025 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
Imexpharm has 154.01 million shares outstanding. The number of shares has decreased by -1.93% in one year.
| Current Share Class | 154.01M |
| Shares Outstanding | 154.01M |
| Shares Change (YoY) | -1.93% |
| Shares Change (QoQ) | -7.30% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.26% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 25.60.
| PE Ratio | 25.60 |
| Forward PE | n/a |
| PS Ratio | 3.43 |
| PB Ratio | 3.52 |
| P/TBV Ratio | 3.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 77.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.63, with an EV/FCF ratio of -5,531.42.
| EV / Earnings | 25.39 |
| EV / Sales | 3.40 |
| EV / EBITDA | 14.63 |
| EV / EBIT | 18.15 |
| EV / FCF | -5,531.42 |
Financial Position
The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.17.
| Current Ratio | 4.48 |
| Quick Ratio | 2.11 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.73 |
| Debt / FCF | -274.10 |
| Interest Coverage | 81.35 |
Financial Efficiency
Return on equity (ROE) is 15.18% and return on invested capital (ROIC) is 11.03%.
| Return on Equity (ROE) | 15.18% |
| Return on Assets (ROA) | 10.04% |
| Return on Invested Capital (ROIC) | 11.03% |
| Return on Capital Employed (ROCE) | 17.27% |
| Revenue Per Employee | 1.60B |
| Profits Per Employee | 213.81M |
| Employee Count | 1,452 |
| Asset Turnover | 0.86 |
| Inventory Turnover | 1.79 |
Taxes
In the past 12 months, Imexpharm has paid 88.31 billion in taxes.
| Income Tax | 88.31B |
| Effective Tax Rate | 20.94% |
Stock Price Statistics
The stock price has increased by +49.10% in the last 52 weeks. The beta is 0.75, so Imexpharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | +49.10% |
| 50-Day Moving Average | 48,849.00 |
| 200-Day Moving Average | 46,989.50 |
| Relative Strength Index (RSI) | 54.97 |
| Average Volume (20 Days) | 105,172 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imexpharm had revenue of VND 2.31 trillion and earned 309.16 billion in profits. Earnings per share was 2,007.45.
| Revenue | 2.31T |
| Gross Profit | 1.09T |
| Operating Income | 432.60B |
| Pretax Income | 421.71B |
| Net Income | 309.16B |
| EBITDA | 536.47B |
| EBIT | 432.60B |
| Earnings Per Share (EPS) | 2,007.45 |
Balance Sheet
The company has 455.35 billion in cash and 388.98 billion in debt, giving a net cash position of 66.38 billion or 430.98 per share.
| Cash & Cash Equivalents | 455.35B |
| Total Debt | 388.98B |
| Net Cash | 66.38B |
| Net Cash Per Share | 430.98 |
| Equity (Book Value) | 2.25T |
| Book Value Per Share | 14,593.83 |
| Working Capital | 1.43T |
Cash Flow
In the last 12 months, operating cash flow was 102.55 billion and capital expenditures -103.97 billion, giving a free cash flow of -1.42 billion.
| Operating Cash Flow | 102.55B |
| Capital Expenditures | -103.97B |
| Free Cash Flow | -1.42B |
| FCF Per Share | -9.21 |
Margins
Gross margin is 47.15%, with operating and profit margins of 18.74% and 14.45%.
| Gross Margin | 47.15% |
| Operating Margin | 18.74% |
| Pretax Margin | 18.27% |
| Profit Margin | 14.45% |
| EBITDA Margin | 23.24% |
| EBIT Margin | 18.74% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.97%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 0.97% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 21.00% |
| Buyback Yield | 1.93% |
| Shareholder Yield | 2.91% |
| Earnings Yield | 3.91% |
| FCF Yield | -0.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Sep 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Imexpharm has an Altman Z-Score of 7.91 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.91 |
| Piotroski F-Score | 6 |